Research graph
References from Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies. Local targets link to admitted publications; unresolved targets remain external evidence.
Lecanemab in early Alzheimer's disease
10.1056/nejmoa2212948 · 2023 · External reference
Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER‐ALZ 2 randomized clinical trial
10.1001/jama.2023.13239 · 2023 · External reference
Two randomized phase 3 studies of aducanumab in early Alzheimer's disease
10.14283/jpad.2022.30 · 2022 · External reference
Two phase 3 trials of gantenerumab in early Alzheimer's disease
10.1056/nejmoa2304430 · 2023 · External reference
Implications of the approval of Lecanemab for Alzheimer disease patient care: incremental step or paradigm shift?
10.1212/wnl.0000000000207438 · 2023 · External reference
Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER‐ALZ randomized clinical trial
10.1001/jamaneurol.2022.2793 · 2022 · External reference
Posttreatment amyloid levels and clinical outcomes following donanemab for early symptomatic Alzheimer disease
10.1001/jamaneurol.2025.3869 · 2025 · External reference
Concurrent changes in plasma phosphorylated tau 217, tau PET, and cognition in preclinical Alzheimer disease
10.1001/jamaneurol.2025.2974 · 2025 · External reference
An insider's perspective on FDA approval of aducanumab
10.1002/trc2.12382 · 2023 · External reference
Treatment‐related amyloid clearance (TRAC): a framework to characterize patients in the era of anti‐amyloid therapies
10.1002/alz.70997 · 2025 · External reference
Maximizing the benefit and managing the risk of anti‐amyloid monoclonal antibody therapy for Alzheimer's disease: strategies and research directions
10.1016/j.neurot.2025.e00570 · 2025 · External reference
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
10.1002/alz.13859 · 2024 · External reference
A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease
10.1016/j.tjpad.2025.100458 · 2026 · External reference
Defining imaging biomarker cut points for brain aging and Alzheimer's disease
10.1016/j.jalz.2016.08.005 · 2017 · External reference
Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium
10.1002/alz.14336 · 2024 · External reference
Comparison of amyloid PET measured in centiloid units with neuropathological findings in Alzheimer's disease
10.1186/s13195-020-00587-5 · 2020 · External reference
Defining the Lowest Threshold for Amyloid‐PET to Predict Future Cognitive Decline and Amyloid Accumulation
10.1212/wnl.0000000000011214 · 2021 · External reference
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
10.1038/nature19323 · 2016 · External reference
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
10.1001/archneurol.2011.1538 · 2012 · External reference
A semiautomated method for quantification of F 18 florbetapir PET images
10.2967/jnumed.114.153494 · 2015 · External reference
Investigating partially discordant results in phase 3 studies of aducanumab
10.14283/jpad.2023.6 · 2023 · External reference
Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease
10.1016/j.tjpad.2025.100202 · 2025 · External reference
Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials
10.1016/j.trci.2019.06.005 · 2019 · External reference
Appropriate use of meaningful within‐patient change (MWPC) thresholds in Alzheimer's disease
10.1002/alz.14436 · 2025 · External reference
Temporal dynamics of beta‐amyloid accumulation in aging and Alzheimer disease
10.1212/wnl.0000000000011524 · 2021 · External reference
